Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426021 | 0.98 | LTA4H (0.32) | LTA4HOPRM1OPRD1OPRK1 | |
| SCHEMBL23736374 | 0.93 | LTA4H (0.33) | LTA4HCYP2D6CYP1A2OPRM1OPRD1 | |
| SCHEMBL1548847 | 0.93 | CYP2D6 (0.35) | LTA4HCYP2D6CYP1A2OPRM1OPRD1 | |
| SCHEMBL23736366 | 0.91 | LTA4H (0.33) | LTA4HCYP2D6CYP1A2DRD2DRD4 | |
| SCHEMBL23736383 | 0.91 | LTA4H (0.33) | LTA4HCYP2D6CYP1A2DRD2DRD4 | |
| SCHEMBL3429155 | 0.91 | — | — | |
| SCHEMBL522366 | 0.91 | LTA4H (0.37) | LTA4HCYP2D6CYP1A2OPRM1OPRD1 | |
| SCHEMBL11209044 | 0.89 | LTA4H (0.36) | LTA4HCYP2D6CYP1A2OPRM1OPRD1 | |
| SCHEMBL79285 | 0.88 | LTA4H (0.39) | LTA4HCYP2D6CYP1A2OPRM1OPRD1 | |
| SCHEMBL6567107 | 0.88 | LTA4H (0.39) | LTA4HCYP2D6CYP1A2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558648-B2 | Amine compound, acid gas absorbent, method for removing acid gas, and acid gas removal apparatus | KABUSHIKI KAISHA TOSHIBA (JP) | 2026-02-24 | — | — | US | claimed |
| US-11090603-B2 | Acidic gas absorbent, acidic gas removal method and acidic gas removal apparatus | KABUSHIKI KAISHA TOSHIBA (JP) | 2021-08-17 | — | — | US | claimed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | claimed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | claimed |
| US-12558648-B2 | Amine compound, acid gas absorbent, method for removing acid gas, and acid gas removal apparatus | KABUSHIKI KAISHA TOSHIBA (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20240307817-A1 | ACID GAS ABSORBENT, METHOD FOR REMOVING ACID GAS, AND ACID GAS REMOVAL APPARATUS | KABUSHIKI KAISHA TOSHIBA (JP) | 2024-09-19 | — | — | US | disclosed |
| US-20230104687-A1 | NOVEL AMINE COMPOUND, ACID GAS ABSORBENT, METHOD FOR REMOVING ACID GAS, AND ACID GAS REMOVAL APPARATUS | KABUSHIKI KAISHA TOSHIBA (JP) | 2023-04-06 | — | — | US | disclosed |
| CN-115805003-A | Novel amine compound, acid gas absorbent, method for removing acid gas, and acid gas removal device | 株式会社东芝 | 2023-03-17 | — | — | CN | disclosed |
| US-11090603-B2 | Acidic gas absorbent, acidic gas removal method and acidic gas removal apparatus | KABUSHIKI KAISHA TOSHIBA (JP) | 2021-08-17 | — | — | US | disclosed |
| CN-1809557-B | Compound | ASTRAZENECA AB | 2012-07-04 | — | — | CN | disclosed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| EP-1644361-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
| WO-2004113324-A1 | CHINAZOLINE DERIVATIVES AS AURORA KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
| EP-1463506-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | Astrazeneca AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055491-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178382-A1 | Chinazoline derivatives as aurora kinase inhibitors | AURKA, AURKC, AURKB | LTA4H 4830/4885CYP2D6 3311/4885CYP1A2 1039/4885 |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | LTA4H 4849/4885CYP2D6 3294/4885CYP1A2 2009/4885 |
| US-12558648-B2 | Amine compound, acid gas absorbent, method for removing acid gas, and acid gas removal apparatus | ADRB2, ADRA1D, HRH2 | LTA4H 1228/4885CYP2D6 784/4885CYP1A2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.